1. Di Pilato V, Willison E, Marchese A. The microbiology and pathogenesis of nonfermenting Gram-negative infections. Current Opinion in Infectious Diseases. 2023;36(6):537-44.
2. Koulenti D, Vandana KE, Rello J. Current viewpoint on the epidemiology of nonfermenting Gram-negative bacterial strains. Current opinion in infectious diseases. 2023;36(6):545-54.
3. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clinical microbiology reviews. 2008;21(3):538-82.
4. Towner K. Acinetobacter: an old friend, but a new enemy. Journal of Hospital Infection. 2009;73(4):355-63.
5. Jesudason T. WHO publishes updated list of bacterial priority pathogens. The Lancet Microbe. 2024;5(9).
6. Genus Acinetobacter. https://wwwbacterionet/genus/acinetobacter. Erişim Tarihi: 20.10.2024.
7. De la Maza LM, Pezzlo MT, Bittencourt CE, Peterson EM. Color atlas of medical bacteriology: John Wiley & Sons; 2020.
8. Standartları UM, Rehberi BHLT. Cilt II. TC Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu Başkanlığı Mikrobiyoloji Referans Laboratuvarları Daire Başkanlığı, Ankara. 2014.
9. Inchai J, Pothirat C, Bumroongkit C, Limsukon A, Khositsakulchai W, Liwsrisakun C. Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-asso-
ciated pneumonia. Journal of intensive care. 2015;3:1-8.
10. Uwingabiye J, Frikh M, Lemnouer A, Bssaibis F, Belefquih B, Maleb A, et al. Acinetobacter infections prevalence and frequency of the antibiotics resistance: comparative study of intensive care
units versus other hospital units. Pan African Medical Journal. 2016;23(1).
11. Ma C, McClean S. Mapping global prevalence of Acinetobacter baumannii and recent vaccine development to tackle it. Vaccines. 2021;9(6):570.
12. Doi Y, Murray GL, Peleg AY, editors. Acinetobacter baumannii: evolution of antimicrobial resistance—treatment options. Seminars in respiratory and critical care medicine; 2015: Thieme
Medical Publishers.
13. Castanheira M, Mendes RE, Gales AC. Global epidemiology and mechanisms of resistance of Acinetobacter baumannii-calcoaceticus complex. Clinical Infectious Diseases. 2023;76(Supple-
ment_2):S166-S78.
14. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report 2023. Stockholm: ECDC; 2024. .
15. Sedat Kaygusuz KHCHH, Çiğdem Hatice Torun Edis, Emine Yıldırım Gözel, Dilek Altun. Ulusal Sağlık Hizmeti İlişkili Enfeksiyonlar Sürveyan Ağı (USHİESA) 2023 Özet Raporu. T.C. Sağlık
Bakanlığı Halk Sağlığı Genel Müdürlüğü Bulaşıcı Hastalıklar ve Erken Uyarı Dairesi Başkanlığı. 2024:44.
16. Lucidi M, Visaggio D, Migliaccio A, Capecchi G, Visca P, Imperi F, et al. Pathogenicity and virulence of Acinetobacter baumannii: Factors contributing to the fitness in healthcare settings and
the infected host. Virulence. 2024;15(1):2289769.
17. Lee C-R, Lee JH, Park M, Park KS, Bae IK, Kim YB, et al. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Frontiers in
cellular and infection microbiology. 2017;7:55.
18. Gedefie A, Demsis W, Ashagrie M, Kassa Y, Tesfaye M, Tilahun M, et al. Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: a review. Infection and drug resistance.
2021:3711-9.
19. Özdede M, Zarakolu P, Metan G, Köseoğlu Eser Ö, Selimova C, Kızılkaya C, et al. Predictive modeling of mortality in carbapenem-resistant Acinetobacter baumannii bloodstream infections
using machine learning. Journal of investigative medicine: the official publication of the American Federation for Clinical Research. 2024.
20. Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of
infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection. 2022;28(4):521-47.
21. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections.
Clinical infectious diseases. 2024:ciae403.
22. Zhang S, Di L, Qi Y, Qian X, Wang S. Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii. Frontiers in Cellular and Infection Microbiology. 2024;14:1395260.
23. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clinical mic-
robiology reviews. 2009;22(4):582-610.
24. Paz-Zarza VM, Mangwani-Mordani S, Martínez-Maldonado A, Álvarez-Hernández D, Solano-Gálvez SG, Vázquez-López R. Pseudomonas aeruginosa: pathogenicity and antimicrobial resis-
tance in urinary tract infection. Revista chilena de infectologia: organo oficial de la Sociedad Chilena de Infectologia. 2019;36(2):180-9.
25. Procop GW, Church DL, Hall GS, Janda WM. Koneman’s color atlas and textbook of diagnostic microbiology: Jones & Bartlett Learning; 2020.
26. Stefan Riedel SM, Timothy Mietzner, Steve Miller Jawetz, Melnick & Adelberg’s Medical Microbiology 28th Edition. McGraw Hill Professional. 2019.
27. Ochner H, Böhning J, Wang Z, Tarafder AK, Caspy I, Bharat TA. Structure of the Pseudomonas aeruginosa PAO1 Type IV pilus. PLoS pathogens. 2024;20(12):e1012773.
28. Dang J, Wang T, Wen J, Liang H. An important role of the type VI secretion system of Pseudomonas aeruginosa regulated by dnr in response to anaerobic environments. Microbiology Spect-
rum. 2022;10(6):e01533-22.
29. Rocha AJ, Barsottini MRdO, Rocha RR, Laurindo MV, Moraes FLLd, Rocha SLd. Pseudomonas aeruginosa: virulence factors and antibiotic resistance genes. Brazilian Archives of Biology and
Technology. 2019;62:e19180503.
30. Bennett JE, Raphael Dolin, Martin J. Blaser. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Elsevier health sciences. 2019.
31. Murray PR, Rosenthal KS, Pfaller MA. Medical microbiology, 9th Edition: Elsevier Health Sciences; 2020.
32. Lamere L. Pseudomonas Infection Outbreak Associated with a Hotel Swimming Pool—Maine, March 2023. MMWR Morbidity and Mortality Weekly Report. 2024;73.
33. Farzin A, Rahman MM, Mollika FA. Pseudomonas aeruginosa: the alarming pathogen of hospital acquired infection. 2023.
34. Krell T, Matilla MA. Pseudomonas aeruginosa. Trends in microbiology. 2024;32(2):216-8.
35. GÜRPINAR Ö, Köseoğlu-Eser Ö. Pseudomonas aeruginosa Resistome and Epidemic High-Risk Clones Pseudomonas aeruginosa Rezistomu ve Epidemik Yüksek Riskli Klonları. Klimik
Dergisi. 2022;35(2).
36. Montero MM, Domene-Ochoa S, Prim N, Ferola E, López-Causapé C, Echeverria D, et al. Synergistic efficacy of ceftazidime/avibactam and aztreonam against carbapenemase-producing
Pseudomonas aeruginosa: insights from the hollow-fiber infection model. Infectious Diseases. 2024:1-8.
37. Reynolds D, Kollef M. The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update. Drugs. 2021;81(18):2117-31.
38. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clinical microbiology reviews. 1998;11(1):57-80.
39. Genus Stenotrophomonas. https://lpsndsmzde/genus/stenotrophomonas. Erişim Tarihi: 10.12.2025.
40. Banar M, Sattari-Maraji A, Bayatinejad G, Ebrahimi E, Jabalameli L, Beigverdi R, et al. Global prevalence and antibiotic resistance in clinical isolates of Stenotrophomonas maltophilia: a sys-
tematic review and meta-analysis. Frontiers in Medicine. 2023;10:1163439.
41. Mendes ET, Paez JIG, Ferraz JR, Marchi AP, Silva ILAFe, Batista MV, et al. Clinical and microbiological characteristics of patients colonized or infected by Stenotrophomonas maltophilia: is
resistance to sulfamethoxazole/trimethoprim a problem? Revista do Instituto de Medicina Tropical de São Paulo. 2020;62:e96.
42. Mikhailovich V, Heydarov R, Zimenkov D, Chebotar I. Stenotrophomonas maltophilia virulence: a current view. Frontiers in Microbiology. 2024;15:1385631.
43. Brooke JS. Advances in the microbiology of Stenotrophomonas maltophilia. Clinical microbiology reviews. 2021;34(3):10.1128/cmr. 00030-19.
44. Gao S, Zhang Z, Zhou H, Zhu H, Shen H, Zhou W. Complete genome sequence of oxidase-positive Stenotrophomonas maltophilia strain SM7059. Microbiology Resource Announcements.
2019;8(17):10.1128/mra. 01576-18.
45. Mojica MF, Humphries R, Lipuma JJ, Mathers AJ, Rao GG, Shelburne SA, et al. Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC-antimicrobial Resistance.
2022;4(3):dlac040.
46. Liaw S-J, Lee Y-L, Hsueh P-R. Multidrug resistance in clinical isolates of Stenotrophomonas maltophilia: roles of integrons, efflux pumps, phosphoglucomutase (SpgM), and melanin and
biofilm formation. International journal of antimicrobial agents. 2010;35(2):126-30.
47. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 34th ed. CLSI supplement M100; 2024. https://clsi.org/all-free-resources/.
Erişim Tarihi: 10.12.2024.
48. Elshafie HS, Camele I. An overview of metabolic activity, beneficial and pathogenic aspects of Burkholderia Spp. Metabolites. 2021;11(5):321.
49. Palleroni NJ. Burkholderia. Bergey’s Manual of Systematics of Archaea and Bacteria. 2015:1-50.
50. Häfliger E, Atkinson A, Marschall J. Systematic review of healthcare-associated Burkholderia cepacia complex outbreaks: presentation, causes and outbreak control. Infection prevention in
practice. 2020;2(3):100082.
51. About Melioidosis. https://wwwcdcgov/melioidosis/about/indexhtml Erişim Tarihi: 10.12.2024.
52. Melioidosis (Burkholderia pseudomallei) 2023 Case Definition. https://ndcservicescdcgov/case-definitions/melioidosis-burkholderia-pseudomallei-2023/. Erişim Tarihi: 10.12.2024.
53. Radu VD, Onofrei P, Vaida M, Costache RC. Urinary tract infections with Burkholderia cepacia. A narrative review. Archive of Clinical Cases. 2024;11(3):86.
54. Marrs EC, Perry A, Perry JD. Evaluation of three culture media for isolation of Burkholderia cepacia complex from respiratory samples of patients with cystic fibrosis. Microorganisms.
2021;9(12):2604.
55. Lauman P, Dennis JJ. Advances in phage therapy: targeting the Burkholderia cepacia complex. Viruses. 2021;13(7):1331.